Sirtex Medical (ASX:SRX) has completed patient recruitment for the SORAMIC study in patients with inoperable primary liver cancer, also known as hepatocellular carcinoma or HCC.
Professor Jens Ricke, global Co-Principal Investigator of the SORAMIC study and director of the Clinic for Radiology and Nuclear Medicine at the University of Magdeburg, said: “For the past ten years, sorafenib has been the sole standard of care for treating patients with advanced HCC, or any HCC that has spread beyond the liver. We hope that the results of this large RCT will demonstrate that the combination of sorafenib and SIR-Spheres microspheres may provide a new treatment standard for patients with HCC who are not eligible for surgical resection or ablation.”
Sorafenib is available through the PBS for HCC and renal cell carcinoma as Bayer's NEXAVAR.
According to Mr Gilman Wong, CEO of Sirtex Medical, “SORAMIC is the fourth clinical study to complete patient recruitment across our five major clinical studies program, and represents the largest SIR-Spheres Y-90 resin microspheres combination study ever undertaken in HCC. We eagerly await the results of the study, which are anticipated to be available in 2018.”
The primary endpoint of the SORAMIC study is Overall Survival with key secondary endpoints of quality of life and safety. A total of 420 patients were recruited into the palliative arm of the study.